For reduced risk of chronic disease and a better chance at a longer life, midlife weight loss may be helpful, a new study ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

MD, CFPC, FCFP, Family Physician, discusses What is Chronic Obstructive Pulmonary Disease.

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

The AERIFY program includes two additional ongoing trials: AERIFY-3, a Phase 2 mechanistic study assessing the impact of itepekimab on airway inflammation in patients with COPD, and AERIFY-4, a Phase ...

Regeneron Pharmaceuticals declined by 16.7 percent last week as investors sold off positions amid the surprising failure of ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...